[go: up one dir, main page]

WO2017046776A3 - Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis - Google Patents

Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis Download PDF

Info

Publication number
WO2017046776A3
WO2017046776A3 PCT/IB2016/055559 IB2016055559W WO2017046776A3 WO 2017046776 A3 WO2017046776 A3 WO 2017046776A3 IB 2016055559 W IB2016055559 W IB 2016055559W WO 2017046776 A3 WO2017046776 A3 WO 2017046776A3
Authority
WO
WIPO (PCT)
Prior art keywords
arteritis
treatment
takayasu
prophylaxis
giant cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2016/055559
Other languages
French (fr)
Other versions
WO2017046776A2 (en
Inventor
Yue Liu
Patrick Garidel
Andreas Langer
Kenneth Flanagan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prothena Biosciences Ltd
Original Assignee
Prothena Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Ltd filed Critical Prothena Biosciences Ltd
Priority to CA2998716A priority Critical patent/CA2998716A1/en
Priority to EP16770571.4A priority patent/EP3350226A2/en
Priority to JP2018513643A priority patent/JP2018530540A/en
Publication of WO2017046776A2 publication Critical patent/WO2017046776A2/en
Publication of WO2017046776A3 publication Critical patent/WO2017046776A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention provides anti-MCAM antibodies that inhibit the ability of human MCAM to bind a laminin alpha-4 chain and pharmaceutical compositions and pharmaceutical formulations incorporating the same for use in treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica (PMR) or Takayasu's arteritis, methods of generating such antibodies, and their use in the manufacture of medicaments for treatment of neuroinflammatory disease, autoimmune disease, or cancer.
PCT/IB2016/055559 2015-09-16 2016-09-16 Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis Ceased WO2017046776A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA2998716A CA2998716A1 (en) 2015-09-16 2016-09-16 Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
EP16770571.4A EP3350226A2 (en) 2015-09-16 2016-09-16 Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
JP2018513643A JP2018530540A (en) 2015-09-16 2016-09-16 Use of anti-MCAM antibodies for the treatment or prevention of giant cell arteritis, polymyalgia rheumatica or Takayasu arteritis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562219599P 2015-09-16 2015-09-16
US62/219,599 2015-09-16

Publications (2)

Publication Number Publication Date
WO2017046776A2 WO2017046776A2 (en) 2017-03-23
WO2017046776A3 true WO2017046776A3 (en) 2017-05-04

Family

ID=56990689

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2016/055559 Ceased WO2017046776A2 (en) 2015-09-16 2016-09-16 Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis

Country Status (4)

Country Link
EP (1) EP3350226A2 (en)
JP (1) JP2018530540A (en)
CA (1) CA2998716A1 (en)
WO (1) WO2017046776A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI660972B (en) 2012-09-10 2019-06-01 愛爾蘭商尼歐托普生物科學公司 Anti-mcam antibodies and associated methods of use
CA2938933A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg4-5
ES2744526T3 (en) 2014-03-12 2020-02-25 Prothena Biosciences Ltd Anti-MCAM antibodies and associated methods of use
WO2017208210A1 (en) * 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
JP7575102B2 (en) * 2018-12-21 2024-10-29 マルチチュード インコーポレーテッド MUC18-specific antibodies
AU2019401657B2 (en) 2018-12-21 2025-10-09 Multitude Therapeutics Inc. Antibodies specific to MUC18
EP4463135A2 (en) 2022-01-10 2024-11-20 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
EP4602174A1 (en) 2022-10-13 2025-08-20 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
EP4627096A1 (en) 2022-12-02 2025-10-08 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
AU2024274792A1 (en) 2023-05-23 2025-10-23 Sana Biotechnology, Inc. Tandem fusogens and related lipid particles
CN117069848B (en) * 2023-08-02 2025-02-28 武汉爱博泰克生物科技有限公司 Anti-human CD146 rabbit monoclonal antibody and its application
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110217237A1 (en) * 2010-03-02 2011-09-08 Abbott Laboratories Therapeutic dll4 binding proteins
WO2012024187A1 (en) * 2010-08-14 2012-02-23 Abbott Laboratories Amyloid-beta binding proteins
WO2012170071A1 (en) * 2011-06-06 2012-12-13 Elan Pharmaceuticas, Inc Mcam antagonists and methods of treatment
US20130216556A1 (en) * 2012-02-16 2013-08-22 Santarus, Inc. Antibody formulations
WO2013164789A2 (en) * 2012-05-04 2013-11-07 Novartis Ag Antibody formulatoin
WO2013186700A1 (en) * 2012-06-12 2013-12-19 Novartis Ag Antibody formulation
WO2014039975A2 (en) * 2012-09-10 2014-03-13 Neotope Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2015061584A1 (en) * 2013-10-24 2015-04-30 Medimmune, Llc Stable, aqueous antibody formulations
WO2015136470A1 (en) * 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (en) 1982-01-22 1985-10-31 Sandoz Ag METHOD FOR IN VITRO PRODUCTION OF HYBRID OMEN WHAT human monoclonal antibodies GENERATE.
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DE69133566T2 (en) 1990-01-12 2007-12-06 Amgen Fremont Inc. Formation of xenogenic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
KR100272077B1 (en) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
DE69230142T2 (en) 1991-05-15 2000-03-09 Cambridge Antibody Technology Ltd. METHOD FOR PRODUCING SPECIFIC BINDING PAIRS
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5877218A (en) 1994-01-10 1999-03-02 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
DE19539493A1 (en) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Strong homologous promoter from hamster
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
EP1005368B1 (en) 1997-03-10 2009-09-02 Ottawa Hospital Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide in combination with alum as adjuvants
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
CA2361492A1 (en) 1999-02-05 2000-08-10 Samsung Electronics Co., Ltd. Image texture retrieving method and apparatus thereof
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
EP1470146B8 (en) 2001-12-28 2007-09-12 Amgen Fremont Inc. Antibodies against the muc18 antigen
JP2005516965A (en) 2001-12-28 2005-06-09 アブジェニックス・インコーポレーテッド Method using anti-MUC18 antibody
JP2005514409A (en) 2001-12-28 2005-05-19 アブジェニックス・インコーポレーテッド Use of antibodies against MUC18 antigen
MXPA05005481A (en) 2002-11-29 2005-07-25 Boehringer Ingelheim Pharma Novel neomycin phosphotransferase genes and method for the selection of high-producing recombinant cells.
DE10338531A1 (en) 2003-08-19 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method for recloning production cells
PT1820022E (en) 2004-11-10 2009-08-05 Boehringer Ingelheim Pharma Use of flow-cytometric analysis to optimize cell banking strategies for cho cells
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
ES2523915T5 (en) 2006-12-01 2022-05-26 Seagen Inc Variant Target Binding Agents and Uses Thereof
WO2008107388A1 (en) 2007-03-02 2008-09-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Improvement of protein production
EP2031064A1 (en) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Method for increasing protein titres

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110217237A1 (en) * 2010-03-02 2011-09-08 Abbott Laboratories Therapeutic dll4 binding proteins
WO2012024187A1 (en) * 2010-08-14 2012-02-23 Abbott Laboratories Amyloid-beta binding proteins
WO2012170071A1 (en) * 2011-06-06 2012-12-13 Elan Pharmaceuticas, Inc Mcam antagonists and methods of treatment
US20130216556A1 (en) * 2012-02-16 2013-08-22 Santarus, Inc. Antibody formulations
WO2013164789A2 (en) * 2012-05-04 2013-11-07 Novartis Ag Antibody formulatoin
WO2013186700A1 (en) * 2012-06-12 2013-12-19 Novartis Ag Antibody formulation
WO2014039975A2 (en) * 2012-09-10 2014-03-13 Neotope Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2015061584A1 (en) * 2013-10-24 2015-04-30 Medimmune, Llc Stable, aqueous antibody formulations
WO2015136470A1 (en) * 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LORICERA JAVIER ET AL: "Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients", SEMINARS IN ARTHRITIS AND RHEUMATISM, vol. 44, no. 6, 27 December 2014 (2014-12-27), pages 717 - 723, XP029229325, ISSN: 0049-0172, DOI: 10.1016/J.SEMARTHRIT.2014.12.005 *
YING ZHANG ET AL: "Generation and Characterization of a Panel of Monoclonal Antibodies Against Distinct Epitopes of Human CD146", HYBRIDOMA, vol. 27, no. 5, 1 October 2008 (2008-10-01), pages 345 - 352, XP055155690, ISSN: 1554-0014, DOI: 10.1089/hyb.2008.0034 *
ZHENG C ET AL: "Endothelial CD146 is required for in vitro tumor-induced angiogenesis: The role of a disulfide bond in signaling and dimerization", INTERNATIONAL JOURNAL OF BIOCHEMISTRY AND CELL BIOLOGY, PERGAMON, GB, vol. 41, no. 11, 1 November 2009 (2009-11-01), pages 2163 - 2172, XP026644025, ISSN: 1357-2725, [retrieved on 20090405], DOI: 10.1016/J.BIOCEL.2009.03.014 *

Also Published As

Publication number Publication date
WO2017046776A2 (en) 2017-03-23
CA2998716A1 (en) 2017-03-23
JP2018530540A (en) 2018-10-18
EP3350226A2 (en) 2018-07-25

Similar Documents

Publication Publication Date Title
WO2017046776A3 (en) Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017046774A3 (en) Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
PH12018501281A1 (en) Human immunodeficiency virus neutralizing antibodies
PH12019501824A1 (en) Anti-gprc5d antibody and molecule comprising the antibody
EA201691836A1 (en) ANTIBODIES TO MCAM AND RELATED METHODS OF THEIR APPLICATION
WO2017030823A3 (en) Anti-tigit antibodies
WO2017062619A3 (en) Combination therapy for the treatment of cancer
PH12017500803A1 (en) Anti-pd-1 antibodies
MY188879A (en) Glycan therapeutics and related methods thereof
HK1250990A1 (en) Factor xi antibodies and methods of use
WO2015157629A3 (en) Antibodies, pharmaceutical compositions and uses thereof
WO2016004305A3 (en) Inhibitors of bruton's tyrosine kinase
MX2019007347A (en) Anti-cd3 antibody, and molecule containing said antibody.
WO2014180889A8 (en) Methods and compositions for the treatment of cancer
WO2017049038A3 (en) Anti-cd115 antibodies
WO2017136731A8 (en) Rapaglutins, novel inhibitors of glut and use thereof
MX2017006437A (en) Spiro-isoquinoline-1,4'-piperidine compounds having multimodal activity against pain.
WO2017062615A3 (en) Combination therapy for the treatment of cancer
MX2020002802A (en) Heavy chain antibodies binding to ectoenzymes.
WO2017117070A8 (en) Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof
HK1259083A1 (en) Methods and compositions for treating systemic mastocytosis
HK1254231A1 (en) Mito-honokiol compounds and methods of synthesis and use thereof
WO2018087143A3 (en) Anti-pd-1 antibodies
WO2015044961A3 (en) Pharmaceutical composition comprising capecitabine and cyclophosphamide
PH12022551500A1 (en) Bispecific anti-ccl2 antibodies

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16770571

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2998716

Country of ref document: CA

Ref document number: 2018513643

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2016770571

Country of ref document: EP